A Phase 3 interventional study of Inclisiran Sodium in ASCVD, Elevated Cholesterol and Heterozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 238 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.
Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 13 in phase 3, and was the 5th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Duke University · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,275 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 375 across the 24 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
36 studies in Hypercholesterolemia by Novartis: 6 open now, 10 under way, 5 of them phase 3. Of 26 finished, 10 (38%) have results posted.
Among the 36 studies in Hypercholesterolemia by Novartis, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2019, is one of 17 in phase 3, and was the 11th registered.
Novartis’s Hypercholesterolemia studies by the year they started, since 2002.
5 of the studies testing inclisiran in Hypercholesterolemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 24 studies testing inclisiran in Hypercholesterolemia, from their registry updates:
Among Novartis’s 36 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
This study was an open label, long term extension study in subjects with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalents (eg, diabetes and familial hypercholesterolemia), or heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of LDL-C lowering therapies who have completed the inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3; NCT03060577), or any of the following Phase III lipid lowering studies: MDCO-PCS-17-03 (ORION-9; NCT03397121), MDCO-PCS-17-04 (ORION-10; NCT03399370), or MDCO-PCS-17-08 (ORION-11; NCT03400800).
The End of Study (EOS) visit in the previous feeder studies was Day 1 in this extension study.The duration that each subject participated in this study was a maximum of 3 years. However, for subjects from the Study ORION-3, the Sponsor decided to end the study prior to completion of their full 3-year of participation. It is recorded in the database as discontinuation was due to Sponsor's decision.
In this Phase III extension study, the same study drug of inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) was administered as a single subcutaneous (SC) dose every 180 days from the last dose in previous feeder study (except for subjects newly initiating inclisiran, who received the first two doses 90 days apart) until the end of the study.
On Day 1 (EOS visit in the feeder study), subjects from the previous feeder studies received blinded study medication except subjects from Study ORION-3. Subjects who received placebo in the previous Phase III feeder study received blinded inclisiran and subjects who received inclisiran in the previous feeder study received blinded placebo at this visit, so that subjects previously on placebo received the correct dosing regime, i.e. a dose at Day 1, Day 90 and every 180-days thereafter. Subjects previously treated with inclisiran did not need a dose of inclisiran to maintain every 180-dosing regime and therefore, were given placebo in order to maintain the blinding of the feeder study. Subjects that moved over from ORION-3 received the first study medication at Day 90, as this study was already open-label.
On Day 90, all subjects received inclisiran sodium 300 mg. This is 180 days after the last injection in the previous feeder study for subjects that received inclisiran and was the second dose of inclisiran for the subjects that received placebo in the feeder study. The EOS visit occurred at Day 1080.
This extension study allowed subjects continued access to inclisiran treatment and allowed the collection of additional efficacy and safety data for long-term use beyond the end of the feeder studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Females who are pregnant or nursing, or who are of and unwilling to use at least one method of acceptable effective (eg, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:
Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran sodium 300 milligrams (mg) was administered as a single SC injection on Day 1\*, 90, then every 180 days to Day 990. \*Subjects who received blinded placebo in the feeder study received blinded inclisiran and subjects who received blinded inclisiran in the feeder study received blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study did not receive any injection of study drug on Day 1. Their first dose of study medication was at day 90
Drug: Inclisiran Sodium
Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk
The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS). Target is \<70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and \<100 mg/dL for ASCVD risk equivalent subjects. Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease.
Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)
Incidence of Treatment-emergent Adverse Events (TEAEs)
Safety assessments include adverse events and serious adverse events until the end of study. End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit.
Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)
Absolute Change in LDL-C From the Initial Feeder Study Baseline
Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Percentage Change in LDL-C From the Initial Feeder Study Baseline
Percentage change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Absolute change from baseline in total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Percentage change from baseline in total cholesterol (TC), triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
268 centers in 13 countries: United States(145), Canada(8), Czechia(4), Denmark(6), Germany(9), Hungary(4), Netherlands(12), Poland(18), South Africa(12), Spain(6), Sweden(3), Ukraine(8), United Kingdom(33)
| Milestone | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover |
|---|---|---|---|
| Started | 1513 | 1478 | 284 |
| Safety population | 1512 | 1478 | 284 |
| Completed | 1246 | 1200 | 0 |
| Not completed | 267 | 278 | 284 |
| Withdrew: Sponsor's administrative decision | 0 | 0 | 272 |
| Withdrew: Death | 80 | 81 | 4 |
| Withdrew: Withdrew consent | 77 | 78 | 2 |
| Withdrew: Lost to follow-up | 47 | 52 | 1 |
| Withdrew: Adverse event | 22 | 23 | 0 |
| Withdrew: Physician decision | 7 | 4 | 2 |
| Withdrew: Initiation of protocol-prohibited approved pcsk9 inhibitor | 0 | 0 | 1 |
| Withdrew: Other reasons | 34 | 40 | 2 |
The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS). Target is \<70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and \<100 mg/dL for ASCVD risk equivalent subjects. Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease.
| Percentage of participants | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total |
|---|---|---|---|---|
| % of subjects Who Attain Global Lipid Targets at Day 1080 / EOS | 78.18 (75.8 to 80.4) | 79.07 (76.7 to 81.3) | 76.81 (71.4 to 81.6) | 78.43 (76.8 to 80.0) |
| % of ASCVD subjects Who Attain Global Lipid Targets of <70 mg/dL at Day 1080 / EOS | 79.34 (76.8 to 81.7) | 79.96 (77.4 to 82.4) | 76.70 (70.0 to 82.5) | 79.41 (77.7 to 81.1) |
| % of ASCVD Risk Equivalent subjects Who Attain Global Lipid Targets of <100 mg/dL at Day 1080 / EOS | 72.56 (66.1 to 78.3) | 74.88 (68.6 to 80.5) | 77.00 (67.7 to 84.7) | 74.33 (70.4 to 78.0) |
Safety assessments include adverse events and serious adverse events until the end of study. End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit.
| Participants | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total |
|---|---|---|---|---|
| Adverse events | 1197 | 1170 | 181 | 2548 |
| Adverse events :Treatment-related | 133 | 148 | 16 | 297 |
| SAEs | 464 | 482 | 43 | 989 |
| SAEs: Treatment-related | 2 | 2 | 1 | 5 |
| Fatal SAEs | 80 | 81 | 4 | 165 |
| Fatal SAEs: Treatment-related | 0 | 0 | 0 | 0 |
Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
| mg/dL | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover |
|---|---|---|---|
| ORION-8 Baseline | -55.21 (-56.9 to -53.5) | 0.46 (-1.4 to 2.3) | -61.58 (-66.4 to -56.8) |
| Day 1080 / EOS | -55.81 (-58.0 to -53.6) | -54.70 (-56.9 to -52.5) | -64.31 (-69.0 to -59.7) |
Percentage change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
| Percentage change in LDL-C | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover |
|---|---|---|---|
| ORION-8 Baseline | -50.02 (-51.3 to -48.8) | 3.10 (1.4 to 4.9) | -48.22 (-51.2 to -45.2) |
| Day 1080 / EOS | -48.96 (-50.5 to -47.4) | -49.69 (-51.3 to -48.0) | -49.95 (-52.6 to -47.3) |
Absolute change from baseline in total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
| mg/dL | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover |
|---|---|---|---|
| ORION-8 Baseline Total Cholesterol (TC) | -59.05 (-61.0 to -57.1) | -0.07 (-2.2 to 2.1) | -63.11 (-68.3 to -57.9) |
| Day 1080 / EOS Total Cholesterol (TC) | -58.48 (-61.0 to -55.9) | -57.08 (-59.6 to -54.6) | -65.43 (-70.5 to -60.3) |
| ORION-8 Baseline Triglycerides | -21.50 (-25.1 to -17.9) | -5.74 (-9.5 to -2.0) | -14.43 (-23.7 to -5.1) |
| Day 1080 / EOS Triglycerides | -19.58 (-23.7 to -15.4) | -22.12 (-26.3 to -17.9) | -21.32 (-30.3 to -12.4) |
| ORION-8 Baseline HDL Cholesterol | 3.37 (2.9 to 3.9) | 0.59 (0.1 to 1.1) | 3.41 (2.2 to 4.6) |
| Day 1080 / EOS HDL Cholesterol | 3.60 (3.0 to 4.2) | 4.39 (3.8 to 5.0) | 5.27 (3.8 to 6.7) |
Percentage change from baseline in total cholesterol (TC), triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
| Percentage change | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover |
|---|---|---|---|
| ORION-8 Baseline Total Cholesterol (TC) | -30.64 (-31.5 to -29.7) | 1.28 (0.1 to 2.4) | -29.49 (-31.6 to -27.4) |
| Day 1080 / EOS Total Cholesterol (TC) | -29.34 (-30.5 to -28.2) | -29.53 (-30.7 to -28.4) | -30.44 (-32.4 to -28.5) |
| ORION-8 Baseline Triglycerides | -7.84 (-10.0 to -5.7) | 3.03 (0.8 to 5.2) | -0.20 (-7.6 to 7.2) |
| Day 1080 / EOS Triglycerides | -3.90 (-6.5 to -1.3) | -6.85 (-9.2 to -4.5) | -3.18 (-9.2 to 2.8) |
| ORION-8 Baseline HDL Cholesterol | 9.28 (8.2 to 10.4) | 3.48 (2.4 to 4.6) | 8.13 (5.7 to 10.5) |
| Day 1080 / EOS HDL Cholesterol | 9.91 (8.7 to 11.2) | 11.75 (10.3 to 13.2) | 12.16 (9.3 to 15.0) |
Collected over Adverse events were reported from the start of study in ORION-8 until end of study treatment plus 90 days post treatment, up to a maximum duration of 1080 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase III Inclisiran-Inclisiran | 80/1,512 (5.3%) | 464/1,512 (30.7%) | 1,110/1,512 (73.4%) |
| Phase III Placebo-Inclisiran | 81/1,478 (5.5%) | 482/1,478 (32.6%) | 1,073/1,478 (72.6%) |
| ORION-3 Rollover | 4/284 (1.4%) | 43/284 (15.1%) | 169/284 (59.5%) |
| Total | 165/3,274 (5%) | 989/3,274 (30.2%) | 2,352/3,274 (71.8%) |
| Event | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total |
|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 36/1512 | 26/1478 | 2/284 | 64/3274 |
| COVID-19Infections and infestations | 21/1512 | 28/1478 | 0/284 | 49/3274 |
| Acute myocardial infarctionCardiac disorders | 17/1512 | 24/1478 | 3/284 | 44/3274 |
| COVID-19 pneumoniaInfections and infestations | 14/1512 | 21/1478 | 0/284 | 35/3274 |
| Angina pectorisCardiac disorders | 21/1512 | 20/1478 | 2/284 | 43/3274 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 16/1512 | 20/1478 | 0/284 | 36/3274 |
| Myocardial infarctionCardiac disorders | 12/1512 | 19/1478 | 2/284 | 33/3274 |
| DeathGeneral disorders | 12/1512 | 19/1478 | 2/284 | 33/3274 |
| Angina unstableCardiac disorders | 12/1512 | 18/1478 | 2/284 | 32/3274 |
| PneumoniaInfections and infestations | 16/1512 | 17/1478 | 2/284 | 35/3274 |
| Event | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total |
|---|---|---|---|---|
| COVID-19Infections and infestations | 178/1512 | 176/1478 | 52/284 | 406/3274 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 114/1512 | 109/1478 | 3/284 | 226/3274 |
| HypertensionVascular disorders | 106/1512 | 110/1478 | 9/284 | 225/3274 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 94/1512 | 102/1478 | 5/284 | 201/3274 |
| Diabetes mellitusMetabolism and nutrition disorders | 98/1512 | 100/1478 | 7/284 | 205/3274 |
| Urinary tract infectionInfections and infestations | 77/1512 | 60/1478 | 10/284 | 147/3274 |
| Back painMusculoskeletal and connective tissue disorders | 67/1512 | 51/1478 | 8/284 | 126/3274 |
| NasopharyngitisInfections and infestations | 61/1512 | 44/1478 | 5/284 | 110/3274 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 60/1512 | 53/1478 | 6/284 | 119/3274 |
| Upper respiratory tract infectionInfections and infestations | 56/1512 | 50/1478 | 4/284 | 110/3274 |
Demographic and baseline characteristics are based on the safety population, as primary and secondary analysis are based on the safety population. The safety population consisted of all ORION-3 rollover subjects who signed the informed consent to Study ORION-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study ORION-8
| Age, Continuous(years) | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total |
|---|---|---|---|---|
| Mean | 64.7 ± 9.83 | 64.6 ± 9.82 | 67.7 ± 9.97 | 64.9 ± 9.88 |
| Sex: Female, Male(Participants) | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total |
|---|---|---|---|---|
| Female | 482 | 476 | 100 | 1058 |
| Male | 1030 | 1002 | 184 | 2216 |
| Race/Ethnicity, Customized(Participants) | Phase III Inclisiran-Inclisiran | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total |
|---|---|---|---|---|
| American Indian/Alaska Native | 3 | 2 | 2 | 7 |
| Asian | 17 | 7 | 3 | 27 |
| Black/African American | 103 | 78 | 7 | 188 |
| Native Hawaiian/Other Pacific Islander | 6 | 4 | 0 | 10 |
| White | 1383 | 1387 | 271 | 3041 |
| Missing | 0 | 0 | 1 | 1 |
Showing the first 100 of 238 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2019 to primary completion in Feb 2023, 45 months.
Results were first posted in Mar 2024, 1 year after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 45 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran